All In Biotech

Drug Trial Radar · NCT07690371

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin (NKTR-358) Monotherapy in the Treatment of Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 510 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

510

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

May 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Nektar TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.

Conditions

  • Moderate-to-Severe Atopic Dermatitis

Interventions

  • RezpegaldesleukinDrug

    Pharmaceutical form: Injection solution Route of administration: subcutaneous

  • PlaceboDrug

    Pharmaceutical form: Injection solution Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. US only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 and reduction ≥ 2 points from baseline at Week 24Time frame: Week 0 and Week 24
  2. Non-US regions only: Number of participants with an Investigator's Global Assessment (IGA) score of 0 or 1 at Week 24Time frame: Week 0 and Week 24
  3. Non-US regions only: Number of participants with a ≥ 75% reduction in Eczema Area and Severity Index (EASI) score from baseline at Week 24 (EASI-75)Time frame: Week 0 and Week 24

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Nektar Investigative Site

    Phoenix, Arizona · Recruiting

  • Nektar Investigative Site

    North Little Rock, Arkansas · Recruiting

  • Nektar Investigative Site

    Fountain Valley, California · Recruiting

  • Nektar Investigative Site

    Los Angeles, California · Recruiting

  • Nektar Investigative Site

    Boca Raton, Florida · Recruiting

  • Nektar Investigative Site

    St. Petersburg, Florida · Recruiting

  • Nektar Investigative Site

    Tampa, Florida · Recruiting

  • Nektar Investigative Site

    Macon, Georgia · Recruiting

  • Nektar Investigative Site

    Boise, Idaho · Recruiting

  • Nektar Investigative Site

    Normal, Illinois · Recruiting

  • Nektar Investigative Site

    Bowling Green, Kentucky · Recruiting

  • Nektar Investigative Site

    Owensboro, Kentucky · Recruiting

  • Nektar Investigative Site

    Lafayette, Louisiana · Recruiting

  • Nektar Investigative Site

    Auburn Hills, Michigan · Recruiting

  • Nektar Investigative Site

    Omaha, Nebraska · Recruiting

  • Nektar Investigative Site

    Clifton, New Jersey · Recruiting

  • Nektar Investigative Site

    New York, New York · Recruiting

  • Nektar Investigative Site

    New York, New York · Recruiting

  • Nektar Investigative Site

    Wilmington, North Carolina · Recruiting

  • Nektar Investigative Site

    Oklahoma City, Oklahoma · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.